Mutations in TP53 have previously been associated with improved outcome following immunotherapy-containing regimens in NSCLC [35], and prior analyses of a possible association with RB1 mutational status and immunotherapy outcomes have yielded conflicting evidence, which might be in part attributable to methodologic differences in assessing RB1 functional status [34, 36]. This evidence concerns the gene RB1 and non-small cell lung carcinoma.